Show simple item record

dc.contributor.authorLawton, Frank
dc.contributor.authorBlackledge, G
dc.contributor.authorBuckley, H
dc.contributor.authorJohnson, Richard J
dc.contributor.authorKelly, K
dc.contributor.authorCrowther, Derek
dc.date.accessioned2010-12-02T11:21:55Z
dc.date.available2010-12-02T11:21:55Z
dc.date.issued1985-12
dc.identifier.citationSequential chemotherapy for advanced epithelial ovarian cancer: platinum combination cytoreduction followed by cyclophosphamide consolidation. 1985, 21 (12):1479-83 Eur J Cancer Clin Oncolen
dc.identifier.issn0277-5379
dc.identifier.pmid2420603
dc.identifier.doi10.1016/0277-5379(85)90242-1
dc.identifier.urihttp://hdl.handle.net/10541/116916
dc.description.abstractThirty-six women with advanced epithelial ovarian cancer were treated with a combination of cisplatin, vinblastine and bleomycin followed by a consolidation regimen of intravenous cyclophosphamide. There was a 53% response rate in previously untreated patients with 25% complete clinical remissions. Sixteen per cent of previously untreated patients remain in a complete clinical remission of greater than 3 yr duration. In a multivariate analysis bulk tumor residuum was not a significant adverse factor in terms of survival, suggesting that intensive chemical cytoreduction followed by non-cross-resistant consolidation may overcome such prognostic variables.
dc.language.isoenen
dc.subjectAnticancerous Combined Chemotherapy Protocolsen
dc.subjectOvarian Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBleomycin
dc.subject.meshCisplatin
dc.subject.meshCyclophosphamide
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshOvarian Neoplasms
dc.subject.meshVinblastine
dc.titleSequential chemotherapy for advanced epithelial ovarian cancer: platinum combination cytoreduction followed by cyclophosphamide consolidation.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign, Department of Medical Oncology and Department of Radiology, Christie Hospital and Holt Radium Institute, Wilmslow Rd., Manchester UKen
dc.identifier.journalEuropean Journal of Cancer & Clinical Oncologyen
html.description.abstractThirty-six women with advanced epithelial ovarian cancer were treated with a combination of cisplatin, vinblastine and bleomycin followed by a consolidation regimen of intravenous cyclophosphamide. There was a 53% response rate in previously untreated patients with 25% complete clinical remissions. Sixteen per cent of previously untreated patients remain in a complete clinical remission of greater than 3 yr duration. In a multivariate analysis bulk tumor residuum was not a significant adverse factor in terms of survival, suggesting that intensive chemical cytoreduction followed by non-cross-resistant consolidation may overcome such prognostic variables.


Files in this item

This item appears in the following Collection(s)

Show simple item record